Ex parte Sasajima

Evidence of unexpected results relating to a property not disclosed in the original application, such as the relative toxicity of a claimed pharmaceutical compound, must still be considered in evaluating nonobviousness.

Generated summary for orientation only — not legal advice. Verify against the opinion.